Gewählte Publikation:
Lipp, RW; Hammer, HF; Passath, A; Dobnig, H; Ramschak-Schwarzer, S; Stiegler, C; Leb, G; Krejs, GJ.
Primary and follow-up studies of patients with carcinoid metastases using indium 111 octreotide--rational use of Sandostatin.
Acta Med Austriaca. 1993; 20(1-2):42-44
Web of Science
PubMed
- Führende Autor*innen der Med Uni Graz
-
Lipp Rainer
- Co-Autor*innen der Med Uni Graz
-
Dobnig Harald
-
Hammer Heinz
-
Krejs Günter Josef
-
Leb Georg
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Abstract:
- Carcinoids may express Somatostatin receptors. Therefore, a Somatostatin-analogue, In-111 Octreotide (OctreoScan), was used for their demonstration. A total of 6 patients who presented with radiologically verified carcinoid-metastases was examined. In order to control tumor progress, 4 of these patients were reexamined within a period of 3 to 11 months. All of the radiological findings were confirmed scintigraphically, except some small retroperitoneally located lymph nodes. The follow-up examinations of 2 patients revealed additional metastases by scintigraphy only. There were no false positive results. The results of OctreoScan scintigraphy may be used for predicting the success of receptor-specific therapies and therefore, permit the rational and efficient application of Sandostatin.
- Find related publications in this database (using NLM MeSH Indexing)
-
Aged -
-
Carcinoid Tumor - drug therapy Carcinoid Tumor - radionuclide imaging Carcinoid Tumor - secondary
-
Female -
-
Follow-Up Studies -
-
Humans -
-
Indium Radioisotopes - diagnostic use
-
Intestinal Neoplasms - drug therapy Intestinal Neoplasms - radionuclide imaging
-
Liver Neoplasms - drug therapy Liver Neoplasms - radionuclide imaging Liver Neoplasms - secondary
-
Lymphatic Metastasis -
-
Male -
-
Middle Aged -
-
Octreotide - diagnostic use Octreotide - therapeutic use
- Find related publications in this database (Keywords)
-
Carcinoids
-
Receptor Scintigraphy
-
Octreotide